Emergence of Medetomidine in New York's Illicit Drug Supply.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 41962141.
- Also identified by DOI 10.1056/EVIDpha2600045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
AbstractNew York State and New York City health departments have closely monitored the emergence of medetomidine, a sedative that can cause prolonged sedation and a complex withdrawal syndrome, in the illicit drug supply. Drug checking and toxicology data first detected medetomidine in New York in mid-2024, and through 2025 it was identified in 25.1% of opioid samples analyzed. This Public Health Alerts report highlights state and local collaboration to detect emerging substances of concern in the illicit drug supply and to implement data-guided programmatic responses, including enhanced surveillance, public alerts, and medetomidine test strip distribution.